Accepted Manuscript

Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy

Hanna Nieznanska, Magdalena Bandyszewska, Krystyna Surewicz, Tomasz Zajkowski, Witold K. Surewicz, Krzysztof Nieznanski

PII: S0925-4439(18)30113-3

DOI: doi:10.1016/j.bbadis.2018.03.023

Reference: BBADIS 65094

To appear in:

Received date: 9 November 2017 Revised date: 27 February 2018 Accepted date: 26 March 2018

Please cite this article as: Hanna Nieznanska, Magdalena Bandyszewska, Krystyna Surewicz, Tomasz Zajkowski, Witold K. Surewicz, Krzysztof Nieznanski, Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Bbadis(2018), doi:10.1016/j.bbadis.2018.03.023

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy

Hanna Nieznanska¹, Magdalena Bandyszewska¹, Krystyna Surewicz², Tomasz Zajkowski³, Witold K. Surewicz² and Krzysztof Nieznanski^{1,*}

- ¹ Department of Biochemistry, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093 Warsaw, Poland.
- ² Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, 44106, USA.
- ³ Laboratory of Molecular Neurobiology, Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland.
- * Correspondence to: Krzysztof Nieznanski, Department of Biochemistry, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093 Warsaw, Poland, tel. +48 22 5892318, fax +48 22 8225342, e-mail: k.nieznanski@nencki.gov.pl

ABSTRACT

Soluble form of the prion protein (PrP) has been previously shown to interact with amyloid- β (A β) peptides, suppressing their fibrillization as well as toxicity, which indicates that this protein may play a protective role in Alzheimer's disease (AD). The shortest known PrP fragment retaining all of these properties corresponds to physiologically generated proteolytic polypeptide PrP23-110/111, called N1. Here we have identified two N1-derived synthetic peptides, encompassing residues 23-50 (PrP23-50) and 90-112 (PrP90-112), which bind to A β 1-42 protofibrillar oligomers as well as amyloid fibrils. We found that, akin to N1, the abovementioned synthetic peptides not only reduce the initial rate of A β fibrillization, but also

Download English Version:

https://daneshyari.com/en/article/8258437

Download Persian Version:

https://daneshyari.com/article/8258437

<u>Daneshyari.com</u>